<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811902</url>
  </required_header>
  <id_info>
    <org_study_id>DRI10566</org_study_id>
    <secondary_id>2008-001999-67</secondary_id>
    <nct_id>NCT00811902</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis</brief_title>
  <official_title>A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the activity of nerispirdine in improving the ability to
      walk, in patients with multiple sclerosis (MS).

      Secondary objectives:

        -  To assess other measures of walking ability, tiredness, and lower limb muscular
           strength, spasticity, clinical assessment by subject and clinical assessment of change
           by the Study Investigator

        -  To assess the safety and tolerance of nerispirdine

        -  To evaluate the pharmacokinetics (PK) parameters of nerispirdine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration per patient is approximately 19 weeks in total, comprising a 3-week screening
      period inclusive of a 2-week placebo run-in period, a 14-week treatment period, and a 2-week
      placebo run-out (follow-up) period
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder criterion based on consistency of improved response in walking speed on the Timed 25-Foot Walk (T25-FWT)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in the 12-item MS Walking Scale (MSWS-12)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Nerispirdine 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nerispirdine 50mg once daily for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerispirdine 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nerispirdine 100mg once daily for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerispirdine 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nerispirdine 200mg once daily for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Nerispirdine once daily for 14 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nerispirdine</intervention_name>
    <description>tablet, oral administration</description>
    <arm_group_label>Nerispirdine 50mg</arm_group_label>
    <arm_group_label>Nerispirdine 100mg</arm_group_label>
    <arm_group_label>Nerispirdine 200mg</arm_group_label>
    <other_name>HP184</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet, oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically definite MS (according to McDonald criteria),

        Exclusion Criteria:

          -  Multiple sclerosis exacerbation or clinical relapse within 6-month prior to the
             screening visit.

          -  Subject who is not able to complete two trials of a timed 25 foot walk, with or
             without an assisted device,

          -  Patients without valid V1, V2, and V4 T25-FW measurements are not eligible for
             randomization.

          -  Female patients who are either pregnant or breastfeeding.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lysaker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <disposition_first_submitted>January 28, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 26, 2016</disposition_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

